drugset / Trial / NCT01059448
Safety and Efficacy of AMG 827 in Subjects With RA
NaSingle-groupOpen-labelTreatment
Summary
This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989). All subjects in this study will receive a 210mg injection of AMG827 for treatment for their Rheumatoid Arthritis for up to 5 years.
Timeline
- Start
- 2010-06-03
- Primary completion
- 2011-04-05
- Completion
- 2011-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |